Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Brandy Norwood stars in “Christmas Everyday,” an all-new Lifetime holiday movie, premiering Saturday, Nov. 29, at 8 p.m. ET. Amid to chaos of trying to uphold her father’s cherished Christmas ...

The festive film is about 'faith, family, and the true meaning of Christmas,' a press release says. By Tim Chan All products and services featured are independently chosen by editors. However, ...

“Christmas Everyday” follows Fancy and her family as they spend their first Christmas together without their father. With her sister’s wedding coming up and her mother starting to lose her sight, ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...